Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic ...

Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% ...

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen ...

A teenage carer from Carmarthenshire sat a GCSE exam only hours after getting home from a hospital at 3am following a family ...

Abstract: Epilepsy is a recurrent neurological disorder, and nearly 30% of patients with epilepsy continue to experience symptoms despite taking anti-epileptic drugs. Predicting epileptic seizures ...

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces CMSF in CDKL5 deficiency disorder: Brussels, Belgium Tuesday, December 9, 2 ...

Senior corrections and health staff will change how they respond to health emergencies inside NT jails, following the ...

A new advance from Carnegie Mellon University researchers could reshape how clinicians identify the brain regions responsible for drug-resistant epilepsy.

A new advance from Carnegie Mellon University researchers could reshape how clinicians identify the brain regions responsible ...

Data presented at the 2025 American Epilepsy Society Annual MeetingPLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of ...

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company ...